Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients

Table 3 Serum LH and testosterone efficacy parameters according to “on versus off LH-RH agonist” in the validation cohort

Marker	Sensitivity	Specificity	Efficiency	PPV^a	NPV^b
Serum LH^c	124/126 (98.4)	17/17 (100)	141/142(98.6)	124/124 (100)	17/17 (89.5)
Serum testosterone (CLIA)^d	106/126 (84.1)	6/17 (35.3)	112/143 (78.3)	106/117 (90.6)	6/26 (23.1)
Serum testosterone (LC MSMS)^e	123/126 (97.6)	5/17 (29.4)	128/143 (89.5)	123/135 (91.1)	5/8 (62.5)

^a PPV positive predictive value, ^b NPV negative predictive value, ^c LH Luteinizing hormone, ^d CLIA Chemiluminiscent immunoassay, ^e LC MSMS Liquid chromatography tandem mass espectrometry